Management of gastroesophageal reflux disease.
The primary treatment goals in patients with gastroesophageal reflux disease are relief of symptoms, prevention of symptom relapse, healing of erosive esophagitis, and prevention of complications of esophagitis. In patients with reflux esophagitis, treatment is directed at acid suppression through the use of lifestyle modifications (e.g., elevating the head of the bed, modifying the size and composition of meals) and pharmacologic agents (a histamine H2-receptor antagonist [H2RA] taken on demand or a proton pump inhibitor IPPI] taken 30 to 60 minutes before the first meal of the day). The preferred empiric approach is step-up therapy (treat initially with an H2RA for eight weeks; if symptoms do not improve, change to a PPI) or step-down therapy (treat initially with a PPI; then titrate to the lowest effective medication type and dosage). In patients with erosive esophagitis identified on endoscopy, a PPI is the initial treatment of choice. Diagnostic testing should be reserved for patients who exhibit warning signs (i.e., weight loss, dysphagia, gastrointestinal bleeding) and patients who are at risk for complications of esophagitis (i.e., esophageal stricture formation, Barrett's esophagus, adenocarcinoma). Antireflux surgery, including open and laparoscopic versions of Nissen fundoplication, is an alternative treatment in patients who have chronic reflux with recalcitrant symptoms. Newer endoscopic modalities, including the Stretta and endocinch procedures, are less invasive and have fewer complications than antireflux surgery, but response rates are lower.
Heidelbaugh
Joel J
JJ
Department of Family Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. jheidel@umich.edu
Nostrant
Timothy T
TT
Kim
Clara
C
Van Harrison
R
R
D000863:Antacids / Q000627:therapeutic use; D013505:Digestive System Surgical Procedures / Q000009:adverse effects / Q000379:methods; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000628:therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D054328:Proton Pump Inhibitors; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
D000863:Antacids; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors